

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1681)

DISCLOSURE PURSUANT TO RULE 13.18 OF THE LISTING RULES

This announcement is made by Consun Pharmaceutical Group Limited (the “**Company**”) pursuant to Rule 13.18 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

On 17 March 2017, the Company signed a commitment letter (the “**Commitment Letter**”) with BNP Paribas (being the parent company of BNP Paribas Securities (Asia) Limited), acting through its Hong Kong Branch (the “**Lender**”), pursuant to which the Lender conditionally (conditions include but not limited to the signing of formal facility documents) agreed to grant the Company a three year term loan facility of up to HK\$560,000,000 (the “**Loan Facility**”) commencing from the date of the signing of formal facility documents. The purpose of the Loan Facility is for the payment of consideration of the Share Buy-back as mentioned in the Company’s announcement dated 6 February 2017.

Pursuant to the Commitment Letter, if (a) Mr. AN Yubao (“**Mr. AN**”, the current Chairman of the Company’s Board of Directors) and Central Success Developments Limited (which is wholly owned by Mr. AN) and Ms. LI Qian (“**Ms. LI**”, a current Executive Director and the Chief Executive Officer of the Company) and Double Grace International Limited (which is wholly owned by Ms. LI) cease collectively to (i) be the beneficial owners, either directly or indirectly, of at least 30% of the issued share capital of the Company or (ii) be the single largest shareholder, either directly or indirectly, of the Company; or (b) Central Success Developments Limited ceases to be wholly-owned by Mr. AN and/or his family; or (c) Double Grace International Limited ceases to be wholly-owned by Ms. LI and/or her family, which each of them will constitute an event of default, all outstanding amounts under the Loan Facility (including principal and interest) shall become immediately due and payable.

As at the date of this announcement, Mr. AN and Ms. LI are collectively interested in approximately 34.57% of the Company’s total number of issued shares.

The Company will make continuing disclosure in its subsequent annual and interim reports pursuant to the requirements of Rule 13.21 of the Listing Rules so long as the abovementioned obligations continue to exist.

By order of the Board of
Consun Pharmaceutical Group Limited
AN Yubao
Chairman

Hong Kong, 17 March 2017

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian and Professor ZHU Quan as executive Directors; Mr. WANG Shunlong and Mr. LIN Sheng as non-executive Directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHENG Xinxin as independent non-executive Directors.